We are initiating a new age of pulmonary hypertension (PH) research by holistically addressing unmet needs across the patient journey.

This research will target earlier diagnosis, better monitoring and new treatment approaches. Our focus combines drug discovery and developments that could change the course of the disease, looking at novel therapeutic devices and non-invasive diagnostics involving data analytics, biomarkers, imaging technologies and digital health solutions.

We aim to advance therapies that target the unmet needs in PH and we see scope for enhancing our treatment portfolio to provide more options for patients. New clinical trials have begun, exploring new indications and evaluating current therapeutic agents to provide us with a deeper understanding of how we can achieve optimal patient management.

As Janssen, we won’t stop until we have worked to our full potential to close the diagnosis gap, create the next generation of treatments for patients and ultimately use our expertise to find a way to address the unmet needs we have identified in PH. We have strong research and development skills and resources and we will continue to partner with those who can support our shared goal to enhance the patient journey.